Molecular Probes distribution contract reinstated

Cytomyx Holdings, a leading provider of drug discovery products and services, is pleased to announce that Cambridge BioScience, its UK based research products business, has entered into a non-exclusive distribution agreement with Invitrogen Corporation to distribute Molecular Probes' products.

Molecular Probes was acquired by Invitrogen in August 2003, resulting in the termination of Cambridge BioScience's previous distribution agreement with Molecular Probes at the end of May 2004.

This distribution relationship has now been re-established for an initial term of two years. While the Company believes it is too early to forecast the impact on future sales and profitability, the agreement is seen as being a positive development, which highlights the effectiveness of Cambridge BioScience's distribution capabilities within the UK life science market.

Mike Kerins, Cytomyx' chief executive, said: 'We are delighted to be working with Molecular Probes once again. Sales of its products had historically contributed significant revenues to the company and we look forward to re-establishing a proportion of this business in the future. Since we shall be selling the Molecular Probes range alongside the Invitrogen sales force it is difficult to predict the level of sales that we will be able to achieve, but early indications suggest that a number of major accounts are planning to purchase products directly from us once more.'